Go offline with the Player FM app!
Unlocking the Uveoscleral Pathway: Adam Szaronos on Bio-Interventional Innovation in Glaucoma
Manage episode 479031746 series 2286865
In this edition of The Rob & Jai Show, the OIS Podcast welcomes Adam Szaronos, CEO of IanTrek, for a wide-ranging conversation on innovation, leadership, and unlocking new pathways in glaucoma care. Adam walks us through his career journey from Alcon to TearLab to leading IanTrek, where he’s now championing a new class of glaucoma procedures with AloeFlow™—a minimally invasive, tissue-based implant that activates the uveoscleral pathway.
Together with hosts Dr. Rob Rothman and Dr. Jai Parekh, Adam discusses:
- The evolution of his career from medical device sales to surgical commercialization and C-suite leadership.
- Why the uveoscleral pathway, long leveraged in pharmacology, has remained unaddressed in surgical glaucoma—and how IanTrek is changing that.
- The material science breakthrough that differentiates AloeFlow™ from past uveoscleral attempts like CyPass.
- The market opportunity for post-MiGs patients and how IanTrek’s platform opens new treatment options without burning surgical real estate.
- Insights into IanTrek’s growing bio-interventional pipeline and what’s ahead in 2025 and beyond.
Whether you’re a glaucoma surgeon, an investor, or a medtech strategist, this episode is a must-listen on where glaucoma innovation is headed.
Subscribe to the OIS Podcast today and stay connected to the future of ophthalmology.
419 episodes
Manage episode 479031746 series 2286865
In this edition of The Rob & Jai Show, the OIS Podcast welcomes Adam Szaronos, CEO of IanTrek, for a wide-ranging conversation on innovation, leadership, and unlocking new pathways in glaucoma care. Adam walks us through his career journey from Alcon to TearLab to leading IanTrek, where he’s now championing a new class of glaucoma procedures with AloeFlow™—a minimally invasive, tissue-based implant that activates the uveoscleral pathway.
Together with hosts Dr. Rob Rothman and Dr. Jai Parekh, Adam discusses:
- The evolution of his career from medical device sales to surgical commercialization and C-suite leadership.
- Why the uveoscleral pathway, long leveraged in pharmacology, has remained unaddressed in surgical glaucoma—and how IanTrek is changing that.
- The material science breakthrough that differentiates AloeFlow™ from past uveoscleral attempts like CyPass.
- The market opportunity for post-MiGs patients and how IanTrek’s platform opens new treatment options without burning surgical real estate.
- Insights into IanTrek’s growing bio-interventional pipeline and what’s ahead in 2025 and beyond.
Whether you’re a glaucoma surgeon, an investor, or a medtech strategist, this episode is a must-listen on where glaucoma innovation is headed.
Subscribe to the OIS Podcast today and stay connected to the future of ophthalmology.
419 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.